SIETES :: 92956 citas

Resultados de la búsqueda por CYP3A4 REFINAR BÚSQUEDA

1.

Anónimo. FDA approves new treatment for adults with migraine. U.S. Food and Drug Administration 2019:23 de diciembre. [Ref.ID 103240]

2.

Newman CB, Preiss D, Tobert JA, Jacobson TA, Page II RL, Goldstein LB, Chin C, Tannock LR, Miller M, Raghuveer G, Duell PB, Brinton EA, Pollak A, Braun LT, Welty FK. Statin safety and associated adverse events: a scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2019;39:enero. [Ref.ID 103011]

3.

Hammann F, Gotta V, Conen K, Medinger M, Cesana P, Rochlitz C, Taegtmeyer AB. Pharmacokinetic interaction between taxanes and amiodarone leading to severe toxicity. Br J Clin Pharmacol 2017;83:927-30. [Ref.ID 101972]

4.

Nalla P, Dacruz TA, Obuobie K. Tiredness in a patient treated with itraconazole. BMJ 2017;356:i6819. [Ref.ID 101383]

5.

Anónimo. Cannabis and cannabinoids. Med Lett Drugs Ther 2016;58:97-8. [Ref.ID 100510]

6.

Woloshin S, Schwartz LM. US Food and Drug Administration approval of flibanserin. Even the score does not add up . JAMA Intern Med 2016;176:439-42. [Ref.ID 100071]

7.

Anónimo. Darunavir + cobicistat. Prescrire 2015;35:649. [Ref.ID 99709]

8.

Anónimo. Cobicistat. Prescrire 2015;35:648-9. [Ref.ID 99708]

9.

Herman AO. FDA approves drug for hypoactive sexual desire disorder in women. Journal Watch 2015:1. [Ref.ID 99407]

10.

Young K. FDA advisers back approval of first drug for female sexual dysfunction. Journal Watch 2015:1. [Ref.ID 99241]

11.

Anónimo. Suvorexant (Belsomra) for insomnia. Med Lett Drugs Ther 2015;57:29-31. [Ref.ID 98878]

12.

Degner D. Severe adverse reactions associated with quetiapine. BMJ 2015;350:h1575. [Ref.ID 98872]

13.

Li DQ, Kim R, McArthur E, Fleet JL, Bailey DG, Juurlink D, Shariff SZ, Gomes T, Mamdani M, Gandhi S, Dixon S, Garg AX. Risk of adverse events among older adults following co-prescription of clarithromycin and statins not metabolized by cytochrome P450 3A4. Can Med Assoc J 2015;187:174-80. [Ref.ID 98758]

14.

Mostaza JM, Lahoz C, Morales-Olivas F, Pinto X, Tranche S, Suárez-Tembra M. Riesgo de interacciones farmacológicas por la coadministración de estatinas con fármacos metabolizados por la isoenzima 3A4 del citocromo P450. Med Clin (Barc) 2014;143:427-32. [Ref.ID 98296]

15.

Anónimo. Ginkgo biloba: diminution d'efficacité de l'éfavirenz. Prescrire 2014;34:749. [Ref.ID 98264]

16.

Anónimo. Vorapaxar (Zontivity) for prevention of thrombotic cardiovascular events. Med Lett Drugs Ther 2014;56:85-6. [Ref.ID 98221]

17.

Anónimo. Apremilast (Otezla) for psoriatic arthritis. Med Lett Drugs Ther 2014;56:41-2. [Ref.ID 97916]

18.

Anónimo. Colchicine: encore des morts. Prescrire 2014;34:266. [Ref.ID 97438]

19.

Anónimo. Perampanel (Fycompa) for epilepsy. Med Lett Drugs Ther 2014;56:9-10. [Ref.ID 97220]

20.

Anónimo. Simeprevir (Olysio) for chronic hepatitis C. Med Lett Drugs Ther 2014;56:1-2. [Ref.ID 97179]